Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer

Marco Platania, Francesco Agustoni, Barbara Formisano, Milena Vitali, Monika Ducceschi, Filippo Pietrantonio, Nicoletta Zilembo, Francesco Gelsomino, Sara Pusceddu, Roberto Buzzoni

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In order to evaluate the clinical efficacy and the safety profile of molecularly targeted therapies as a palliative approach in elderly populations affected by advanced thoracic neoplasms, we retrospectively studied, in terms of effectiveness and toxicities, a group of pretreated elderly metastatic non-small cell lung cancer (NSCLC) patients admitted to our institution and treated with erlotinib at standard daily/dose. Forty-three patients aged 70 years or older who had previously failed on chemotherapy or radiotherapy were treated with oral Eerlotinib (150 mg/d) until disease progression or unacceptable toxicity. Clinical data, pathological types, potential prognostic factors, efficacy and toxicity of erlotinib were included in this analysis. In our series we observed: objective responses in six patients (14%) and stable disease in 15 (35%). Skin rash was the most common side effect (67%). Grade 3-4 adverse events were observed in 16 cases (37%). The median overall survival and the median progression-free survival were 8.4 months (CI 95%: 0.7-43.6) and 3 months (CI 95%: 0.4-28.4), respectively. Patients with adenocarcinoma achieved the best disease control rate (p=0.027), while not/former smokers showed a better response (p=0.069). In our experience the use of erlotinib after chemotherapy failure in an unselected elderly population affected by NSCLC showed moderate efficacy and a moderate safety profile. However, erlotinib represents a valid option in this setting, but other factors such as biological information, comorbidities and concomitant medications need to be carefully take into consideration in this particular subset of cancer patients.

Original languageEnglish
Pages (from-to)181-186
Number of pages6
JournalTargeted Oncology
Volume6
Issue number3
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Non-Small Cell Lung Carcinoma
Thoracic Neoplasms
Therapeutics
Safety
Drug Therapy
Exanthema
Population
Disease-Free Survival
Disease Progression
Comorbidity
Adenocarcinoma
Radiotherapy
Erlotinib Hydrochloride
Survival
Neoplasms

Keywords

  • EGFR
  • Elderly patients
  • Erlotinib
  • Non-small cell lung cancer
  • Tyrosine kinase inhibitor (TKI)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. / Platania, Marco; Agustoni, Francesco; Formisano, Barbara; Vitali, Milena; Ducceschi, Monika; Pietrantonio, Filippo; Zilembo, Nicoletta; Gelsomino, Francesco; Pusceddu, Sara; Buzzoni, Roberto.

In: Targeted Oncology, Vol. 6, No. 3, 09.2011, p. 181-186.

Research output: Contribution to journalArticle

Platania, Marco ; Agustoni, Francesco ; Formisano, Barbara ; Vitali, Milena ; Ducceschi, Monika ; Pietrantonio, Filippo ; Zilembo, Nicoletta ; Gelsomino, Francesco ; Pusceddu, Sara ; Buzzoni, Roberto. / Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. In: Targeted Oncology. 2011 ; Vol. 6, No. 3. pp. 181-186.
@article{7f640afe3edf4913924e7b9952f62a9d,
title = "Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer",
abstract = "In order to evaluate the clinical efficacy and the safety profile of molecularly targeted therapies as a palliative approach in elderly populations affected by advanced thoracic neoplasms, we retrospectively studied, in terms of effectiveness and toxicities, a group of pretreated elderly metastatic non-small cell lung cancer (NSCLC) patients admitted to our institution and treated with erlotinib at standard daily/dose. Forty-three patients aged 70 years or older who had previously failed on chemotherapy or radiotherapy were treated with oral Eerlotinib (150 mg/d) until disease progression or unacceptable toxicity. Clinical data, pathological types, potential prognostic factors, efficacy and toxicity of erlotinib were included in this analysis. In our series we observed: objective responses in six patients (14{\%}) and stable disease in 15 (35{\%}). Skin rash was the most common side effect (67{\%}). Grade 3-4 adverse events were observed in 16 cases (37{\%}). The median overall survival and the median progression-free survival were 8.4 months (CI 95{\%}: 0.7-43.6) and 3 months (CI 95{\%}: 0.4-28.4), respectively. Patients with adenocarcinoma achieved the best disease control rate (p=0.027), while not/former smokers showed a better response (p=0.069). In our experience the use of erlotinib after chemotherapy failure in an unselected elderly population affected by NSCLC showed moderate efficacy and a moderate safety profile. However, erlotinib represents a valid option in this setting, but other factors such as biological information, comorbidities and concomitant medications need to be carefully take into consideration in this particular subset of cancer patients.",
keywords = "EGFR, Elderly patients, Erlotinib, Non-small cell lung cancer, Tyrosine kinase inhibitor (TKI)",
author = "Marco Platania and Francesco Agustoni and Barbara Formisano and Milena Vitali and Monika Ducceschi and Filippo Pietrantonio and Nicoletta Zilembo and Francesco Gelsomino and Sara Pusceddu and Roberto Buzzoni",
year = "2011",
month = "9",
doi = "10.1007/s11523-011-0185-6",
language = "English",
volume = "6",
pages = "181--186",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "3",

}

TY - JOUR

T1 - Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer

AU - Platania, Marco

AU - Agustoni, Francesco

AU - Formisano, Barbara

AU - Vitali, Milena

AU - Ducceschi, Monika

AU - Pietrantonio, Filippo

AU - Zilembo, Nicoletta

AU - Gelsomino, Francesco

AU - Pusceddu, Sara

AU - Buzzoni, Roberto

PY - 2011/9

Y1 - 2011/9

N2 - In order to evaluate the clinical efficacy and the safety profile of molecularly targeted therapies as a palliative approach in elderly populations affected by advanced thoracic neoplasms, we retrospectively studied, in terms of effectiveness and toxicities, a group of pretreated elderly metastatic non-small cell lung cancer (NSCLC) patients admitted to our institution and treated with erlotinib at standard daily/dose. Forty-three patients aged 70 years or older who had previously failed on chemotherapy or radiotherapy were treated with oral Eerlotinib (150 mg/d) until disease progression or unacceptable toxicity. Clinical data, pathological types, potential prognostic factors, efficacy and toxicity of erlotinib were included in this analysis. In our series we observed: objective responses in six patients (14%) and stable disease in 15 (35%). Skin rash was the most common side effect (67%). Grade 3-4 adverse events were observed in 16 cases (37%). The median overall survival and the median progression-free survival were 8.4 months (CI 95%: 0.7-43.6) and 3 months (CI 95%: 0.4-28.4), respectively. Patients with adenocarcinoma achieved the best disease control rate (p=0.027), while not/former smokers showed a better response (p=0.069). In our experience the use of erlotinib after chemotherapy failure in an unselected elderly population affected by NSCLC showed moderate efficacy and a moderate safety profile. However, erlotinib represents a valid option in this setting, but other factors such as biological information, comorbidities and concomitant medications need to be carefully take into consideration in this particular subset of cancer patients.

AB - In order to evaluate the clinical efficacy and the safety profile of molecularly targeted therapies as a palliative approach in elderly populations affected by advanced thoracic neoplasms, we retrospectively studied, in terms of effectiveness and toxicities, a group of pretreated elderly metastatic non-small cell lung cancer (NSCLC) patients admitted to our institution and treated with erlotinib at standard daily/dose. Forty-three patients aged 70 years or older who had previously failed on chemotherapy or radiotherapy were treated with oral Eerlotinib (150 mg/d) until disease progression or unacceptable toxicity. Clinical data, pathological types, potential prognostic factors, efficacy and toxicity of erlotinib were included in this analysis. In our series we observed: objective responses in six patients (14%) and stable disease in 15 (35%). Skin rash was the most common side effect (67%). Grade 3-4 adverse events were observed in 16 cases (37%). The median overall survival and the median progression-free survival were 8.4 months (CI 95%: 0.7-43.6) and 3 months (CI 95%: 0.4-28.4), respectively. Patients with adenocarcinoma achieved the best disease control rate (p=0.027), while not/former smokers showed a better response (p=0.069). In our experience the use of erlotinib after chemotherapy failure in an unselected elderly population affected by NSCLC showed moderate efficacy and a moderate safety profile. However, erlotinib represents a valid option in this setting, but other factors such as biological information, comorbidities and concomitant medications need to be carefully take into consideration in this particular subset of cancer patients.

KW - EGFR

KW - Elderly patients

KW - Erlotinib

KW - Non-small cell lung cancer

KW - Tyrosine kinase inhibitor (TKI)

UR - http://www.scopus.com/inward/record.url?scp=81355161551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81355161551&partnerID=8YFLogxK

U2 - 10.1007/s11523-011-0185-6

DO - 10.1007/s11523-011-0185-6

M3 - Article

VL - 6

SP - 181

EP - 186

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 3

ER -